Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Bhatt, Deepak L., Szarek, Michael, Steg, P. Gabriel, Cannon, Christopher P., Leiter, Lawrence A., McGuire, Darren K., Lewis, Julia B., Riddle, Matthew C., Voors, Adriaan A., Metra, Marco, Lund, Lars H., Komajda, Michel, Testani, Jeffrey M., Wilcox, Christopher S., Ponikowski, Piotr, Lopes, Renato D., Verma, Subodh, Lapuerta, Pablo, Pitt, Bertram·2021·New England Journal of Medicine

DOI 10.1056/nejmoa2030183

Cited by (1,000)

Items 601–700 of 1,000

Crosstalk between Sodium–Glucose Cotransporter Inhibitors and Sodium–Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases
Al-Anood Al-Shamasi, Rozina Elkaffash, Meram Mohamed, Menatallah Rayan, Dhabya Al-Khater, Alain‐Pierre Gadeau, Rashid Ahmed, Anwarul Hasan, Hussein Eldassouki, Huseyin Cagatay Yalcin et al. · 2021 · International Journal of Molecular Sciences
Comparative Efficacy of Medical Treatments for Chronic Heart Failure: A Network Meta-Analysis
Boyang Xiang, Zongliang Yu, Xiang Zhou · 2022 · Frontiers in Cardiovascular Medicine
From mid-range to mildly reduced ejection fraction heart failure: A call to treat
Davide Stolfo, Enrico Fabris, Lars H. Lund, Gianluigi Savarese, Gianfranco Sinagra · 2022 · European Journal of Internal Medicine
Polypharmacy in Older People with Heart Failure: Roles of the Geriatrician and Pharmacist
Maria Stefil, Matthew R. Dixon, Jameela Bahar, Schabnam Saied, Knievel Mashida, Olivia Heron, Eduard Shantsila, Lauren E. Walker, Asangaedem Akpan, Gregory Y.H. Lip et al. · 2022 · Cardiac failure review
SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: Finding the right patients to treat
Nicolas Girerd, Faiez M. Zannad · 2023 · Journal of Internal Medicine
Association of sodium-glucose cotransporter 2 inhibitors with post-discharge outcomes in patients with acute heart failure with type 2 diabetes: a cohort study
Sohee Park, Han Eol Jeong, Hyesung Lee, Seng Chan You, Ju‐Young Shin · 2023 · Cardiovascular Diabetology
Underrepresentation of Women in Reduced Ejection Heart Failure Clinical Trials With Improved Mortality or Hospitalization
Eson Ekpo, Sujana Balla, Summer Ngo, Celeste S. Witting, Ashish Sarraju, Adam Furst, Fátima Rodríguez · 2023 · JACC Advances
Sodium glucose co-transporter 2 inhibitors and quality of life in patients with heart failure: a comprehensive systematic review and meta-analysis of randomized controlled trials
Chiara Oriecuia, Daniela Tomasoni, Isabella Sala, Giovanni Battista Bonfioli, Marianna Adamo, Cristina Gussago, Carlo Lombardi, Matteo Pagnesi, Gianluigi Savarese, Marco Metra et al. · 2023 · European Heart Journal - Cardiovascular Pharmacotherapy
Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Patients with CKD
L. Parker Gregg, Peter A. Richardson, Vijay Nambi, Laura A. Petersen, Michael Edwin Matheny, Salim S. Virani, Sankar Dass Navaneethan · 2024 · Journal of the American Society of Nephrology
Long-Term Efficacy of SGLT2 Inhibitors for Elderly Patients with Acute Decompensated Heart Failure: The OASIS-HF Study
Michitaka Amioka, Hiroki Kinoshita, Yuto Fuji, Kazuhiro Nitta, Kenichi Yamane, Tomoki Shokawa, Yukiko Nakano · 2024 · ESC Heart Failure
Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis
Yu‐Min Lin, Jheng‐Yan Wu, Mei-Chuan Lee, Chwen-Yng Su, Han Siong Toh, Wei‐Ting Chang, Sih-Yao Chen, Fang‐Hsiu Kuo, Hsin‐Ju Tang, Chia‐Te Liao · 2025 · European Heart Journal - Cardiovascular Pharmacotherapy
Acute Heart Failure and Non-Ischemic Cardiomyopathies: A Comprehensive Review and Critical Appraisal
Lina Manzi, Federica Buongiorno, Viviana Narciso, Domenico Florimonte, Imma Forzano, Domenico Simone Castiello, Luca Sperandeo, Roberta Paolillo, Nicola Verde, Alessandra Maria Spinelli et al. · 2025 · Diagnostics
Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment
Jaewon Oh, Seung‐Hyun Lee, Chan Joo Lee, Seok‐Min Kang · 2021 · Korean Circulation Journal
Cardiovascular benefit of SGLT2 inhibitors
Reza Mohebi, James L. Januzzi · 2021 · Critical Reviews in Clinical Laboratory Sciences
Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction
Julie K.K. Vishram‐Nielsen, Daniela Tomasoni, Finn Gustafsson, Marco Metra · 2022 · Drugs
The Diabetic Cardiorenal Nexus
John A. D’Elia, George P Bayliss, Larry A. Weinrauch · 2022 · International Journal of Molecular Sciences
Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction
Khawaja Muhammad Talha, Javed Butler · 2022 · Clinical Cardiology
Cost effectiveness analyses of pharmacological treatments in heart failure
Audrey Huili Lim, Nusaibah Abdul Rahim, Jinxin Zhao, S. Y. Amy Cheung, Yu‐Wei Lin · 2022 · Frontiers in Pharmacology
Cardiovascular risk and chronic kidney disease: strategies for cardiac and renal protection. Interdisciplinary consensus
Oksana M. Drapkina, Zhanna D. Kobalava, Marina Vladimirovna Shestakova, Irina Nikolaevna Bobkova, Ефремовцева Марина Алексеевна, Виллевальде Светлана Вадимовна, М. М. Batyushin, Yu. N. Belenkov, Andrey Vatazin, Albert S. Galyavich et al. · 2025 · CARDIOVASCULAR THERAPY AND PREVENTION
Evidentiary Landscape of Heart Failure Therapies, Regulatory Decisions, and Translation Into Guidelines
Sanjay Kaul · 2025 · Journal of the American College of Cardiology
Association of sodium‐glucose cotransporter‐2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD‐REAL 2 study
Carolyn S.P. Lam, Avraham Karasik, Cheli Melzer Cohen, Matthew Aaron Cavender, Shun Kohsaka, Anna Norhammar, Marcus Thuresson, Hungta Chen, Eric T Wittbrodt, Peter Fenici et al. · 2021 · Diabetes Obesity and Metabolism
Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction
Robert John Mentz, Dominik Lautsch, Zulkarnain Pulungan, SEUNG KIM, Robert J. Hilkert, Christie L. Teigland, Mei Yang, Laurence M. Djatche · 2021 · Journal of Cardiac Failure
Effects of SGLT2 inhibitors on cardiac structure and function
Giuseppina Novo, Tommaso Guarino, Daniela Di Lisi, Paolo Biagioli, Erberto Carluccio · 2022 · Heart Failure Reviews
SGLT2 inhibitors for the composite of cardiorenal outcome in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials
Hai‐Bin Chen, Yao‐Lin Yang, Tian-Hao Yu, Yuhui Li · 2022 · European Journal of Pharmacology
Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Sodium–Glucose Co-transporter-2 Inhibitors
Joshua J. Neumiller, Fredrick J Lienhard, Radica Z. Alicic, Katherine R. Tuttle · 2022 · touchREVIEWS in Endocrinology
Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study
Pauline Yeung Ng, Andrew Kei‐Yan Ng, April Ip, Mei‐Zhen Wu, Ran Guo, Kai‐Hang Yiu · 2023 · Critical Care Medicine
Cardiorenal interactions in heart failure: insights from recent therapeutic advances
Kevin Damman, Jeffrey Moore Testani · 2023 · Cardiovascular Research
Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitor Use in Acute Heart Failure Hospitalizations Complicated by AKI
Abinet Mathias Aklilu, Sanchit Kumar, Yu Yamamoto, Dennis G. Moledina, Frederick Sinha, Jeffrey Moore Testani, F. Perry Wilson · 2023 · Kidney360
Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling
Ehab Bakbak, Subodh Verma, Aishwarya Krishnaraj, Adrian Quan, Chao‐Hung Wang, Yi Pan, Pankaj Puar, Tamique Mason, Raj Verma, Daniella C. Terenzi et al. · 2023 · American Journal of Physiology-Heart and Circulatory Physiology
Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis
Yulu Qiu, Xiaoke Feng, Chang Liu, Yumeng Shi, Lingxiao Xu, Hanxiao You, Lei Wang, Chengyin Lv, Fang Wang, Wenfeng Tan · 2024 · Arthritis Research & Therapy
Comparative Effect of Glucose-Lowering Drugs for Type 2 Diabetes Mellitus on Stroke Prevention: A Systematic Review and Network Meta-Analysis
Ji Soo Kim, Gyeongsil Lee, Kyung‐Il Park, Seung‐Won Oh · 2024 · Diabetes & Metabolism Journal
Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
Angelica Cersosimo, Nadia Salerno, Jolanda Sabatino, Alessandra Scatteia, Giandomenico Bisaccia, Salvatore De Rosa, Santo Dellegrottaglie, Chiara Bucciarelli‐Ducci, Daniele Torella, Isabella Leo · 2024 · Cardiovascular Diabetology
Cause-Specific Health Care Costs Following Hospitalization for Heart Failure and Cost Offset With SGLT2i Therapy
Veraprapas Kittipibul, Muthiah Vaduganathan, Uchechukwu Ikeaba, Karen Chiswell, Javed Butler, Adam D. DeVore, Paul A. Heidenreich, Joanna Huang, Michelle Maya Kittleson, Karen E. Joynt Maddox et al. · 2024 · JACC Heart Failure
Cardiovascular outcomes and molecular targets for the cardiac effects of Sodium-Glucose Cotransporter 2 Inhibitors: A systematic review
Rosalinda Madonna, Filippo Biondi, Mattia Alberti, Sandra Ghelardoni, Letizia Mattii, Alberto D’Alleva · 2024 · Biomedicine & Pharmacotherapy
Diagnosis and management of heart failure from hospital admission to discharge: A practical expert guidance
Pierre François Sabouret, David Attias, C. Beauvais, Emmanuelle Berthelot, Claire Bouleti, G. Gibault‐Genty, Arnault Galat, Olivier Hanon, Jean‐Sébastien Hulot, Richard Isnard et al. · 2021 · Annales de Cardiologie et d Angéiologie
Intramuscular injection of sotagliflozin promotes neovascularization in diabetic mice through enhancing skeletal muscle cells paracrine function
Lailiu Luo, Jingxuan Han, Shourong Wu, Vivi Kasim · 2022 · Acta Pharmacologica Sinica
Benefit of sodium-glucose cotransporter-2 inhibitors on survival outcome is related to the type of heart failure: A meta-analysis
Lingyue Zhao, Wenqin Guo, Weichao Huang, Lili Wang, Siquan Huang · 2022 · Diabetes Research and Clinical Practice
Comparison of Serum Ketone Levels and Cardiometabolic Efficacy of Dapagliflozin versus Sitagliptin among Insulin-Treated Chinese Patients with Type 2 Diabetes Mellitus
Chi‐Ho Lee, Mei‐Zhen Wu, David Tak Wai Lui, Darren Shing-Hei Chan, Carol Ho-Yan Fong, Sammy W.M. Shiu, Ying Wong, Alan Chun‐Hong Lee, Joanne K.Y. Lam, Yu Cho Woo et al. · 2022 · Diabetes & Metabolism Journal
Sodium Glucose Co-Transporter 2 Inhibitors Improve Renal Congestion and Left Ventricular Fibrosis in Rats With Hypertensive Heart Failure
Tomofumi Nakatsukasa, Tomoko Ishizu, Masumi Ouchi, Nobuyuki Murakoshi, Kimi Sato, Masayoshi Yamamoto, Kunio Kawanishi, Yoshihiro Seo, Masaki Ieda · 2022 · Circulation Journal
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Sotagliflozin After Multiple Ascending Doses in Chinese Healthy Subjects
Xuemei He, Xin Gao, Panpan Xie, Yuan Liu, Wenjing Bai, Yue Liu, Aixin Shi · 2022 · Drug Design Development and Therapy
Patient preferences for newer oral therapies in type 2 diabetes
Gianluigi Savarese, Abhinav Sharma, Christianne Pang, Richard Wood, Nima Soleymanlou · 2022 · International Journal of Cardiology
Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials
Yaowang Lin, Zhigang Cai, Jie Yuan, Huadong Liu, Xinli Pang, Qiuling Chen, Xinzheng Tang, Qingshan Geng, Shaohong Dong · 2022 · Cardiovascular Diabetology
Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women
Jacob E. Pruett, Seth T. Lirette, Damián G. Romero, Licy L. Yanes Cardozo · 2022 · Journal of the Endocrine Society
Clinical pharmacology of SGLT-2 inhibitors in heart failure
Maria Velliou, Effie Polyzogopoulou, Ioannis Ventoulis, John Parissis · 2023 · Expert Review of Clinical Pharmacology
Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase 2 trial
Ye Yang, Kyung Wan Min, Seok‐O Park, Kyung‐Soo Kim, Jae Myung Yu, Eun‐Gyoung Hong, Sung‐Rae Cho, Kyu Chang Won, Yong Hyun Kim, Seungjoon Oh et al. · 2023 · Diabetes Obesity and Metabolism
Differential effects of sodium–glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes according to renal function: a dose–response meta-analysis involving 10 randomized clinical trials and 71 553 individuals
Donna Shu‐Han Lin, An‐Li Yu, Hao-Yun Lo, Cheng-Wei Lien, Jen‐Kuang Lee, Fu‐Tien Chiang, Yu‐Kang Tu · 2023 · European Journal of Endocrinology
Women and diabetes: preventing heart disease in a new era of therapies
Galati, Giuseppe, Sabouret, Pierre, Germanova, Olga, Bhatt, Deepak L · 2021 · European Cardiology Review
Prognostic and Therapeutic Implications of Renal Insufficiency in Heart Failure
Se Yong Jang, Dong Heon Yang · 2022 · International Journal of Heart Failure
Cardiovascular prevention in elderly patients.
Clara Bonanad, Rosa Fernández-Olmo, Sergio García‐Blas, Jose Antonio Alarcon, Pablo Díez‐Villanueva, Carmen Rus Mansilla, Héctor García‐Pardo, Pablo Toledo, Ana Ayesta, Eva Pereira et al. · 2022 · PubMed Central
In silicodiscovery of potential sodium–glucose cotransporter-2 inhibitors from natural products for treatment of heart failure via molecular docking and molecular dynamics simulation approach
Jiwu Kong, Ling Li, Huicheng Yuan, Feng Bai, Kai Yang, Liangcun Zhao, Shaohua Xu · 2022 · Journal of Biomolecular Structure and Dynamics
SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction — The New Frontier
Inês Aguiar‐Neves, Diogo Santos‐Ferreira, Ricardo Fontes‐Carvalho · 2023 · Reviews in Cardiovascular Medicine
Safety outcomes of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and other risk factors for cardiovascular disease: a systematic review and meta-analysis
Radhika Deshpande, Raj Patel, Manjari Rani Regmi, Mohsin Salih, Robert J. Kropp, Basma Al-bast, Muhammad Adil Sheikh, Andrew Sagalov, Abhishek Kulkarni, Momin Saulat Siddique et al. · 2023 · Cardiovascular Endocrinology & Metabolism
Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials
Minji Sohn, Juan P. Frías, Soo Kyung Lim · 2023 · Diabetes Obesity and Metabolism
Consensus on the approach to hydrosaline overload in acute heart failure. SEMI/SEC/S.E.N. recommendations
Pau Llàcer, Gregorio Romero, Joan Carles Trullàs, Rafael de la Espriella, Marta Cobo, Borja Quiroga, Jesús Casado, María Fernanda Slon-Roblero, José Luís Morales‐Rull, José Ignacio Morgado et al. · 2024 · Revista Española de Cardiología (English Edition)
Harnessing the Synergy of SGLT2 Inhibitors and Continuous Ketone Monitoring (CKM) in Managing Heart Failure among Patients with Type 1 Diabetes
Nicola Tecce, Giorgio de Alteriis, Giulia de Alteriis, Ludovica Verde, Mario Felice Tecce, Annamaria Colao, Giovanna Muscogiuri · 2024 · Healthcare
Effect of SGLT2 inhibitors on anemia and their possible clinical implications
Aleix Cases, Secundino Cigarrán, José Luis Górriz, Julio E. Núñez · 2024 · Nefrología (English Edition)
Heart failure with preserved ejection fraction: The role of inflammation
Hongyi Liu, Ruth Magaye, David M. Kaye, Bing Hui Wang · 2024 · European Journal of Pharmacology
A meta‐analysis of randomized controlled studies examining the effects of sodium‐glucose co‐transporter‐2 inhibitors on peripheral artery disease and risk of amputations
Li Geng, Bing Sun, Yan Chen · 2024 · Diabetes Obesity and Metabolism
Heart Failure and All-Cause Hospitalizations in Patients With Heart Failure
Ahmed A. Sayed, Mohamed ElRefaei, Kamal Awad, Husam Salah, John M. Mandrola, Andrew Foy · 2024 · JAMA Network Open
Eligibility of Outpatients with Chronic Heart Failure for Sodium–Glucose Co-Transporter-2 Inhibitors
Gianmarco Angelini, Miriam Albanese, Raffaella Ursi, Francesco Lisi, Maria Consiglia Bellino, Luca Amato, Margherita Ilaria Gioia, Giuseppe Parisi, Natale Daniele Brunetti, Giuseppina Piazzolla et al. · 2021 · ESC Heart Failure
Update on the Cardiovascular Benefits of Sodium-Glucose Co-Transporter-2 Inhibitors: Mechanism of Action, Available Agents and Comprehensive Review of Literature
Randa Abdelmasih, Ramy Abdelmaseih, Ravi A. Thakker, Mohammed Ali Faluk, Arroj Ali, Mrhaf Alsamman, Syed Mustajab Hasan · 2021 · Cardiology Research
Vulnerable Phase of Acute Heart Failure and its Association with Hospital Readmissions Reduction Program
Azka Latif, Noman Lateef, Scott W. Lundgren, Vikas Kapoor, Muhammad Junaid Ahsan, Ahmed Aboeata · 2021 · Current Problems in Cardiology
The comparative epidemiology and outcomes of hospitalized patients treated with SGLT2 or DPP4 inhibitors
Warren Huang, Jack Whitelaw, Kartik Kishore, Ary Serpa Neto, Natasha E. Holmes, Nada Marhoon, Rinaldo Bellomo, Elif Ilhan Ekinci · 2021 · Journal of Diabetes and its Complications
Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
Marc Evans, Angharad R. Morgan, Stephen Charles Bain, Sarah Davies, Umesh Kumar Dashora, Smeeta Sinha, Samuel Seidu, Dipesh Patel, Hannah Beba, William David Strain · 2022 · Diabetes Therapy
Growing role of SGLT2i in heart failure: evidence from clinical trials
Ajay K. Varadhan, Katarina Stephan, Rahul Gupta, Apurva Vijay Vyas, Purva Ranchal, Wilbert S. Aronow, Nael Hawwa, Gregg M. Lanier · 2022 · Expert Review of Clinical Pharmacology
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes
Oliver Schnell, Tadej Battelino, Richard M. Bergenstal, Matthias Blüher, Michael Böhm, Frank Chip Brosius, Richard David Carr, Antonio Ceriello, Thomas M. Forst, Francesco Giorgino et al. · 2022 · Cardiovascular Diabetology
Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk
Clare Gabrielle Arnott, Robert A. Fletcher, Bruce Charles Neal · 2022 · Heart Failure Clinics
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events
Prakriti Gaba, Deepak L. Bhatt, Gilles R. Dagenais, Jackie Bosch, Aldo Pietro Maggioni, Petr Widimský, Darryl P. Leong, Keith A.A. Fox, Salim Yusuf, John W. Eikelboom et al. · 2022 · JAMA Network Open
Are Arrhythmias the Drivers of Sudden Cardiac Death in Heart Failure with Preserved Ejection Fraction? A Review
Matthew Fomonyuy Yuyun, Scott Kinlay, Jagmeet P. Singh, Jacob Joseph · 2022 · ESC Heart Failure
Cardiovascular outcomes in patients treated with sodium-glucose transport protein 2 inhibitors, a network meta-analysis of randomized trials
Dániel Tornyos, Maximilian Meuer, Réka Lukács, Oumaima El Alaoui El Abdallaoui, Péter Kupó, Réka Faludi, András Komócsi · 2022 · Frontiers in Cardiovascular Medicine
Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis
Xuefeng Li, Hongli Wu, Huifang Peng, Hongwei� Jiang · 2022 · Frontiers in Endocrinology
The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
André Jacques Scheen · 2023 · Expert Review of Endocrinology & Metabolism
Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial
Gian Pio Sorice, Francesca Cinti, Lucia Leccisotti, Domenico D’Amario, Margherita Lorusso, Maria Angela Guzzardi, Teresa Mezza, Camilla Cocchi, Umberto Capece, Pietro Manuel Ferraro et al. · 2021 · Diabetes Therapy
SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era
Konstantinos Grigoriou, Paschalis Karakasis, Athina Nasoufidou, Panagiotis Stachteas, Aleksandra N. Klisic, Efstratios Karagiannidis, Barbara Fyntanidou, Djordje S. Popovic, Dimitrios Patoulias, Antonios P. Antoniadis et al. · 2025 · Medicina
Management of Heart Failure With Preserved Ejection Fraction: 2026 ACC Expert Consensus Decision Pathway
M D Kittleson, Gurusher Singh Panjrath, Katie Bates, Khadijah K Breathett, Dave L. Dixon, James L. Januzzi, Selma F. Mohammed · 2026 · Journal of the American College of Cardiology
Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis
SABOURET, Pierre, BOCCHINO, Pier P., ANGELINI, Filippo, D’ASCENZO, Fabrizio, GALATI, Giuseppe, FYSEKIDIS, Marinos, DE FERRARI, Gaetano M., FISCHMAN, David L., BHATT, Deepak L., BIONDI-ZOCCAI, Giuseppe · 2023 · Minerva Cardiology and Angiology
Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes
McGuire, Darren K., D’Alessio, David, Nicholls, Stephen J., Nissen, Steven E., Riesmeyer, Jeffrey S., Pavo, Imre, Sethuraman, Shanthi, Heilmann, Cory R., Kaiser, John J., Weerakkody, Govinda J. · 2022 · Cardiovascular Diabetology
New Strategies to Prevent Rehospitalizations for Heart Failure
Jamie Elizabeth Diamond, Adam D. DeVore · 2022 · Current Treatment Options in Cardiovascular Medicine
Oxidative Stress Management in Cardiorenal Diseases: Focus on Novel Antidiabetic Agents, Finerenone, and Melatonin
Panagiotis Theofilis, Aikaterini Vordoni, Rigas Kalaitzidis · 2022 · Life
Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure
Masaki Nakagaito, Teruhiko Imamura, Ryuichi Ushijima, Makiko Nakamura, Koichiro Kinugawa · 2023 · Biomedicines
Association between systemic inflammatory response index and left ventricular remodeling and systolic dysfunction in atrial fibrillation patients
Runze Chi, Xiaoli Shan, Chunping Guan, Hao Yang, Xiangkun Wang, Bingong Li, Qing Zhang · 2023 · BMC Cardiovascular Disorders
NEW DIRECTIONS IN PHARMACOLOGICAL TREATMENT WITH SGLT-2 INHIBITOR MOLECULES IN THE LIGHT OF CURRENT GUIDELINES FOR DIABETES MELLITUS, HEART FAILURE AND KIDNEY DISEASE
Mariana Cornelia Tilinca · 2023 · FARMACIA
Congestion in Heart Failure: From the Secret of a Mummy to Today’s Novel Diagnostic and Therapeutic Approaches: A Comprehensive Review
Ioannis Alevroudis, Serafeim‐Chrysovalantis Kotoulas, Stergios Tzikas, Vassilios Pericles Vassilikos · 2023 · Journal of Clinical Medicine
Previous heart failure hospitalization, spironolactone, and outcomes in heart failure with preserved ejection fraction – a secondary analysis of TOPCAT
Barna A. Szabo, Lina Benson, Gianluigi Savarese, Camilla Hage, Marat Fudim, Adam Devore, Bertram Pitt, Lars H. Lund · 2024 · American Heart Journal
Dapagliflozin and Timing of Prior Heart Failure Hospitalization
Jawad H. Butt, Pardeep S. Jhund, Kieran F. Docherty, Brian Lee Claggett, Muthiah Vaduganathan, Erasmus Bachus, Adrian F. Hernandez, Carolyn S.P. Lam, Silvio E. Inzucchi, Felipe A. Martínez et al. · 2024 · JACC Heart Failure
Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial
DAVID H. FITCHETT, Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, Stefan D. Anker, Stuart Pocock, Michaela Mattheus, Ola Vedin, Søren Søgaard Lund · 2024 · Cardiovascular Diabetology
Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure
Ankeet S. Bhatt, Deepak L. Bhatt, Philippe Gabríel Steg, Michael J. Szarek, Christopher Paul Cannon, Lawrence A. Leiter, Darren K. McGuire, Julia Breyer Lewis, Matthew C. Riddle, Adriaan A. Voors et al. · 2024 · Journal of the American College of Cardiology
Redefining outcomes of ventricular arrhythmia for SGLT2 inhibitor medication in heart failure patients: a meta-analysis of randomized controlled trials
Miao Lin, Shiyu Zhang, Lu Zhang, Chengying Yang, Luo Yang, Yajin Peng, Xiaoqiu Tan, Qiang Wen, Xinrong Fan, Xianhong Ou · 2025 · Systematic Reviews
Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility
Giulia Ferrannini, Gianluigi Savarese, Lars Rydén · 2021 · Diabetes Research and Clinical Practice
Does Combination Therapy With SGLT2 Inhibitors and Renin–Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?
Limin Zhao, Miao Zhang, Ze‐Lin Zhan, Mei Qiu · 2021 · Frontiers in Cardiovascular Medicine
Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis
Yao Neng Teo, Yao Hao Teo, Nicholas L. X. Syn, Celine Shuen Yin Yoong, Alex Jia Yang Cheong, Caitlin Fern Wee, Yoke Ching Lim, Chi‐Hang Lee, Tiong‐Cheng Yeo, Ping Chai et al. · 2021 · Clinical Drug Investigation
Quantification and treatment of congestion in heart failure: A clinical and pathophysiological overview
Rafael de la Espriella, Enrique Santas, Isabel Zegrí Reiriz, José Luis Górriz, Marta Cobo Marcos, Julio E. Núñez · 2022 · Nefrología (English Edition)
SGLT2-Inhibitors on HFpEF Patients. Role of Ejection Fraction
Juan Antonio Requena-Ibáñez, Carlos G. Santos‐Gallego, Mohammad Urooj Zafar, Juan J. Badimón · 2022 · Cardiovascular Drugs and Therapy
SGLT2 Inhibitors in Type 2 Diabetes Mellitus
Giulia Ferrannini, Gianluigi Savarese, Francesco Cosentino · 2022 · Heart Failure Clinics
Targeting the ‘Vulnerable’ Period – First 3–6 Months After an Acute Heart Failure Admission – the Light Gets Brighter
Gad Cotter, Beth A. Davison, Alain Cohen Solal, Yonathan Freund, Alexandre Mebazaa · 2022 · European Journal of Heart Failure
Aiming at harmony. Comparing and contrasting International HFrEF Guidelines
Daniela Tomasoni, Marianna Adamo, Biykem Bozkurt, Paul A. Heidenreich, Theresa A. McDonagh, Giuseppe M.C. Rosano, Sean Virani, Shelley R. Zieroth, Marco Metra · 2022 · European Heart Journal Supplements
Efficacy of SGLT2-inhibitors across different definitions of heart failure with preserved ejection fraction
Vincenzo De Marzo, Gianluigi Savarese, Italo Porto, Marco Metra, Pietro Ameri · 2023 · Journal of Cardiovascular Medicine
Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?
Milton Packer · 2023 · Nature Cardiovascular Research
Efecto de los inhibidores del cotransportador sodio-glucosa tipo 2 sobre la anemia: posibles implicaciones clínicas
Aleix Cases, Secundino Cigarrán, José Luis Górriz, Julio E. Núñez · 2023 · Nefrología
Effect of SGLT2 inhibitors on cardiovascular events in patients with atrial fibrillation: A systematic review and meta‐analysis of randomized controlled trials
Shiyue Zheng, Yiwei Lai, Chao Jiang, Liu He, Zixu Zhao, Wenjie Li, Ribo Tang, Caihua Sang, Deyong Long, Xin Du et al. · 2023 · Pacing and Clinical Electrophysiology